Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
F 18.16 3.01% 0.53
URGN closed up 3.01 percent on Thursday, April 15, 2021, on 69 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical URGN trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 3.01%
Bullish Engulfing Bullish 3.01%
Oversold Stochastic Weakness 3.01%
MACD Bearish Signal Line Cross Bearish 3.89%
New 52 Week Closing Low Bearish 3.89%
Hammer Candlestick Bullish 3.89%
Lower Bollinger Band Walk Weakness 3.89%
New 52 Week Low Weakness 3.89%
Older End-of-Day Signals for URGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
Up 2% about 21 hours ago
Up 1% about 21 hours ago
Up 5% 2 days ago
Up 3% 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

UroGen Pharma Ltd. Description

UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Carcinoma Antineoplastic Drugs Bladder Cancer Oab Platform Technologies Overactive Bladder Botulinum Toxin Tlr7 Interstitial Cystitis Non Muscle Invasive Bladder Cancer Urinary Bladder

Is URGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.89
52 Week Low 17.01
Average Volume 209,542
200-Day Moving Average 21.50
50-Day Moving Average 20.84
20-Day Moving Average 18.97
10-Day Moving Average 18.81
Average True Range 1.06
ADX 36.74
+DI 13.34
-DI 27.46
Chandelier Exit (Long, 3 ATRs ) 17.68
Chandelier Exit (Short, 3 ATRs ) 20.19
Upper Bollinger Band 20.57
Lower Bollinger Band 17.38
Percent B (%b) 0.25
BandWidth 16.84
MACD Line -0.61
MACD Signal Line -0.53
MACD Histogram -0.0801
Fundamentals Value
Market Cap 401.21 Million
Num Shares 22.1 Million
EPS -4.89
Price-to-Earnings (P/E) Ratio -3.72
Price-to-Sales 113.10
Price-to-Book 3.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.18
Resistance 3 (R3) 19.09 18.66 19.01
Resistance 2 (R2) 18.66 18.40 18.71 18.95
Resistance 1 (R1) 18.41 18.24 18.54 18.50 18.90
Pivot Point 17.98 17.98 18.04 18.03 17.98
Support 1 (S1) 17.73 17.72 17.86 17.82 17.42
Support 2 (S2) 17.30 17.56 17.35 17.37
Support 3 (S3) 17.05 17.30 17.31
Support 4 (S4) 17.14